Savara Inc. (SVRA)
SVRANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$5.00
+0.0100 (+0.20%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $5.00 +0.20%
- Market cap
- $1.10bn
- P/E
- –
- EPS, last 4 quarters
- $-0.6100
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.00 to $7.01
- Average volume
- –
- Previous close
- $4.99
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $11.67, +133.4% from here
Earnings
next estimate $-0.1700Next report
Dec 2025
-8.3%
Mar 2026
-7.1%
Jun 2026
-14.3%
Sep 2026
+5.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$33.42m | -$38.99m | -$40.97m | -$43.54m |
| Net income | -$32.24m | -$37.28m | -$40.23m | -$42.99m |
News
8 latest- Biotech Stocks Facing FDA Decision In November 2026 RTTNews · Oct 29, 2026
- Notable Thursday Option Activity: SVRA, CAR, SPCXBNK Invest · Sep 24, 2026
- Here's Why You Should Add Savara Stock to Your Portfolio NowZacks · Jul 22, 2026
- What Savara Investors Should Know About This 580,187-Option Exercise and FDA TimelineThe Motley Fool · Jun 27, 2026
- VR Adviser Adds Over 1 Million Savara SharesThe Motley Fool · Mar 15, 2026
- Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets RTTNews · Dec 26, 2025
- HC Wainwright & Co. Maintains Savara (SVRA) Buy RecommendationFintel · Dec 23, 2025
- Savara Resubmits BLA For MOLBREEVI In Autoimmune PAP RTTNews · Dec 23, 2025
The company
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via a proprietary investigational eFlow Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of molgramostim. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- savarapharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.